About Richard Farrell

This author has not yet filled in any details.
So far Richard Farrell has created 12 blog entries.

GABA Therapeutics Receives Approval to Begin Phase I Clinical Trials

We are pleased to provide some positive updates. Inaugural Board Meeting The company held its first Board of Directors meeting in San Francisco in early November. Attendees included (left to right): Srini Rao M.D., Ph.D, Chief Medical Officer, GABA Therapeutics Ian Massey, D.Phil, CEO and Director, GABA Therapeutics Richard [...]

Compared etifoxine to lorazepam (Ativan®) – for alertness and cognitive functions in elderly patients

Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study D. Deplanque, F. Machuron, N. Waucquier, E. Jozefowicz, S. Duhem, S. Somers, O. Colin, A. Duhamel, R. Bordet


Safety Profile of Etifoxine: A French Pharmacovigilance Survey

Adverse drug reactions (ADRs) from over 14 million prescriptions of (Stresam®) etifoxine were reviewed and analyzed by the French National Agency for the Safety of Medicines and Health Products, between 2000 and 2012. The average incidence of ADRs was 0.0021% (21 per million treatments) and no cases of abuse, misuse [...]


Compared etifoxine to alprazolam (Xanax®) – for safety and efficacy

Etifoxine Versus Alprazolam for the Treatment of Adjustment Disorder with Anxiety: a Randomized Controlled Trial Dan J. Stein


Compared etifoxine to lorazepam (Ativan®) – established non-inferiority in adjustment disorder with anxiety ADWA

Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice N. Nguyen, E. Fakra, V. Pradel, E. Jouve, C. Alquier, M-E. Le Guern, J. Micallef, and O. Blin